Division of Shionogi & Co. Ltd.
Latest From Shionogi Ltd.
ViiV Healthcare has asked the European Medicines Agency to accelerate its review of fostemsavir when the company files for pan-EU market approval of the product.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
This week's Pipeline Watch, a snapshot of all the late-stage R&D and regulatory events in the pharma and biotech industries, is now available to view.
Biopharma financing totaled $6.4 billion, a 39% increase over Q3. Twenty-three M&As were completed with a combined potential value of $19.8 billion, and there were 103 biopharma alliances totaling $2.5 billion in potential pre-commercialization value, down 25% from the previous quarter.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.